Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin icodec/semaglutide - Novo Nordisk

X
Drug Profile

Insulin icodec/semaglutide - Novo Nordisk

Alternative Names: Icosema; Insulin icodec/semaglutide; NN 1535; Semaglutide/insulin icodec

Latest Information Update: 15 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Glucagon-like peptide-1 receptor antagonists; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 23 Apr 2024 Novo Nordisk completes a phase-III clinical trial in Type 2 diabetes mellitus (In the elderly, In adults) in Finland, Norway, Croatia, Belgium, Australia, China, India, Japan, South Korea, Mexico, Russia, Serbia, South Africa, Taiwan, Turkey, Italy, Japan, Poland, Portugal, Puerto Rico, Romania and the USA (SC) (NCT05352815)
  • 15 Feb 2024 Phase-III clinical trials in Type 2 diabetes mellitus (Adjunctive treatment, Treatment-experienced) in Turkey, South Africa, Poland, Japan, Italy, Greece, China, USA, India, Puerto Rico (SC) (EudraCT2022-502484-38-00) (NCT06269107)
  • 15 Feb 2024 Phase-III clinical trials in Type 2 diabetes mellitus (Treatment-experienced) in Turkey, South Africa, Puerto Rico, Poland, Greece, Japan, India, Italy, China, USA (SC) (NCT06269107) (EudraCT2022-502484-38-00)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top